Developing CRISPR gene editing for treatment of genetic disease: next-generation sequencing to detect and quantify editing at on- and off-target sites

Navn på bevillingshaver

Jacob Giehm Mikkelsen

Titel

Professor

Institution

Aarhus University

Beløb

DKK 303,365

År

2022

Bevillingstype

Research Infrastructure

Resumé

Discovery of the CRISPR technology, originally identified in bacteria, has made it possible to edit our genes. This technology has enormous potential as a new approach for treating inherited diseases in humans. For development of CRISPR therapies that are clinically relevant, we will study new strategies for delivering gene repair kits to cells. For this type of research, it is pivotal to analyze the gene correction activity at a specific, targeted position in the genome. With this application, we aim at providing the infrastructure for performing targeted gene sequencing by next-generation sequencing. This technique provides high data resolution, deep coverage, and detection of low-frequency gene variants.

Tilbage til oversigtssiden